GE HEALTHCARE’S PHASE 2 RESULTS SUPPORT ADVANCEMENT OF INVESTIGATIONAL MANGANESE-BASED MRI CONTRAST AGENT MANGACICLANOL INTO PHASE 3 OF LUMINA CLINICAL TRIAL

Reuters · 1d ago

Please log in to view news